

CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER'S DISEASE

A. Rodríguez-Alarcón¹, ME. Navarrete-Rouco¹, P. Acín¹, M. Ponce¹, M. Jorques¹, O. Ferrández-Quirante¹, M. Espona¹

¹Hospital del Mar, Pharmacy Department, Barcelona, Spain.

Key words: amyloid plaques, A β amyloid peptide, Alzheimer disease

Abstract number: 4CPS-140
ATC code: N06 – Psychoanaleptics

Background

Alzheimer's disease (AD) is a progressive neurodegenerative process caused by an accumulation of the A β amyloid peptide.

Objectives

The objective of this study is to describe clinical trials' (CT) current status for AD in our hospital pharmacy service and to analyze the investigational drugs.

Material and methods

Observational descriptive retrospective study performed in a tertiary academic hospital from 1st January 2014 until 31st March 2019.

Data collected: total CT and total included patients, demographic data, total of CT classified by: CT status, phase, therapeutic target, administration route, CT with results and type of result.

Results

12 CT for AD were analyzed: 6 (50.0%) CT were in active and 3 (25.0%) CT had results, all of them were negative (3 (100%)).

Demographic data	N=12
Total patients included	59
Patients per CT, mean (rank)	5 (0-8)
Age (years), mean (Rank)	77.4 (71.5-84.7)
Women, n (%)	34 (57.6)

Conclusions

Most number of CT in active were in phase III.
Only 25% CT had results and all of them were negative.
Almost 60% CT has studied the oral administration, which stands out patient's preferences.
There are 5 therapeutic targets currently on study, however, more than 40% CT evaluate AP's reduction.

Based on everything said above, should we re-think the basis of Alzheimer before continuing to develop clinical trials with the same therapeutic target?

